Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

Recession And Budget Cuts Hit Children Especially Hard
As the recession forces more hospitals and doctors to pare costs and services, children are being especially hard hit.
generic viagra online
Bevacizumab (Avastin(R)) Added To Common Chemotherapies Significantly Increases Tumour Shrinkage In HER2-negative Breast Cancer
Data presented at the American Society of Clinical Oncology (ASCO) 2009 meeting, in Orlando, Florida, show that bevacizumab (Avastin®) plus commonly used chemotherapies increases the chance of the patient living without the disease worsening by up to 36% compared to chemotherapies alone, in women receiving first-line therapy for advanced HER2-negative breast cancer. The Phase III RIBBON-1 study combined bevacizumab with chemotherapies, including capecitabine (Xeloda®), taxanes and anthracyclines and measured progression-free survival (PFS).1 No new safety signals for bevacizumab were observed in the study.
News of the day
Novexel To Present Four Posters At The 19th European Congress Of Clinical Microbiology And Infectious Diseases In Helsinki
Novexel, a speciality pharmaceutical company focused on the discovery and development of novel antibiotics designed to overcome the significant global problem of microbial resistance, announces that its two most advanced pipeline products NXL104 and NXL103 are the subject of four posters at the 19th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID). The ECCMID conference is taking place in Helsinki between 16th and 19th May 2009.
Oncology

Accouncing The Leading European Congress On Cardiac Arrhythmias And Pacing: EUROPACE 2009

EUROPACE, the official congress of the European Heart Rhythm Association (EHRA), is the foremost European meeting on cardiac arrhythmias and pacing. More than 4,000 participants are expected to attend this year"s event, whose main themes are atrial fibrillation and sudden cardiac death. EHRA is a registered branch of the European Society of Cardiology (ESC). Its mission is to reduce the impact of cardiac arrhythmias and sudden cardiac death (SCD). EUROPACE 2009 will be held from 21-24 June in ICC Berlin, Germany. The press conference in Berlin will highlight several themes from the EUROPACE 2009 scientific programme: * How to improve the quality of care with a more uniform treatment of arrhythmias and better prevention of sudden cardiac death in all European countries. * Cardiac arrhythmias in athletes will be another important topic. A scientific session will consider the requirement for screening of all athletes to avoid sudden cardiac death and the implications of an abnormal electrocardiogram (ECG) in an athlete. The prevalence of cardiac arrhythmias in the athlete"s heart will be debated. * Hot Line sessions will be a major feature at EUROPACE 2009 (Tuesday 23 June). Devoted to late-breaking news from clinical trials, the ESC"s Hot Line sessions are renowned for making strong stories in medical news and will be discussed at the press conference. Also presented at the press conference: * Remote monitoring * Latest facts and figures on arrhythmias in Europe * Driving with ICD * Beat-It! Campaign Notes: 1. Sudden cardiac death claims more lives than stroke, lung cancer, breast cancer and AIDS combined. Incidence is less than 1% per year in the general population, but rising to more than 30% in high-risk post-MI subgroups. 2. Cardiac arrhythmia describes conditions in which heart beat is too fast, too slow, or irregular. The cause is abnormal electrical activity in the heart. Some arrhythmias may be life-threatening and result in sudden cardiac death. The average healthy heart beats 200,000 times per day. 3. The most common arrhythmia (after a skipped beat) is atrial fibrillation, which affects up to 5 per cent of all adults, mainly the over-65s. * Information on the scientific programme for Europace 2009 is available at http://spo.escardio.org/Welcome.aspx?eevtid=32 ESC Press Office European Society of Cardiology


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009